{
    "eid": "2-s2.0-84900430954",
    "title": "Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers",
    "cover-date": "2014-01-01",
    "subject-areas": [
        {
            "$": "Pharmacology (medical)",
            "@code": "2736"
        },
        {
            "$": "Pharmacology",
            "@code": "3004"
        }
    ],
    "keywords": [
        "Bioequivalence",
        "Irbesartan",
        "Pharmacokinetics",
        "Tablet"
    ],
    "authors": [
        "Supeecha Wittayalertpanya"
    ],
    "citedby-count": 2,
    "ref-count": 11,
    "ref-list": [
        "Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension",
        "Irbesartan: An updated review of its use in cardiovascular disorders",
        "The new angiotensin II receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerations",
        "Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects",
        "Guidance for Industry - Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-general Considerations",
        "Guideline on the Investigation of Bioequivalence",
        "Guidelines for the Conduct of Bioavailability and Bioequivalence Studies",
        "Guidance for Industry - Bioanalytical Method Validation",
        "Liquid chromatographic determination of irbesartan in human plasma",
        "Comparative bioavailability of two irbesartan/hydrochlorothiazide tablet formulations in Indonesian healthy subjects",
        "PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "affilname": "Chulalongkorn University",
        "affiliation-country": "Thailand"
    },
    "funding": []
}